SimpliDerm
Acellular Dermal Matrix for Soft Tissue Reconstruction
ApprovedActive
Key Facts
Indication
Acellular Dermal Matrix for Soft Tissue Reconstruction
Phase
Approved
Status
Active
Company
About Elutia
Elutia is a commercial-stage medical device company developing and marketing innovative drug-eluting biomaterials to combat complications from surgical implants. Its platform technology fuses natural biologic matrices with controlled antibiotic release to create envelopes and matrices for device implantation and soft tissue reconstruction. The company's lead products, CanGaroo and SimpliDerm, target the electrophysiology, neuromodulation, and plastic surgery markets to improve patient outcomes and reduce healthcare costs. Founded in 2019 and led by industry veteran C. Randal Mills, Elutia aims to humanize medicine by ensuring patients can thrive without compromise post-surgery.
View full company profile